Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Aura Biosciences (NASDAQ:AURA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Insider & Institutional Ownership
96.8% of Aura Biosciences shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Contineum Therapeutics and Aura Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | $50.00 million | 6.69 | -$42.26 million | ($2.20) | -5.42 |
| Aura Biosciences | N/A | N/A | -$86.92 million | ($1.96) | -3.13 |
Contineum Therapeutics has higher revenue and earnings than Aura Biosciences. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Contineum Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
Profitability
This table compares Contineum Therapeutics and Aura Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -29.75% | -28.08% |
| Aura Biosciences | N/A | -64.44% | -54.24% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Contineum Therapeutics and Aura Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
| Aura Biosciences | 1 | 1 | 6 | 1 | 2.78 |
Contineum Therapeutics presently has a consensus target price of $22.20, indicating a potential upside of 86.09%. Aura Biosciences has a consensus target price of $22.00, indicating a potential upside of 258.89%. Given Aura Biosciences’ higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Contineum Therapeutics.
Summary
Contineum Therapeutics beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
About Aura Biosciences
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
